LUXEMBOURG – 23 March, 2020 – Inceptua – pharmaceutical company and service partner – and biopharmaceutical company Oxurion have announced a global license agreement for the commercialization of JETREA®, a first-in-class pharmacological vitreolysis therapy approved for treatment of symptomatic vitreomacular adhesion or vitreomacular traction.

Stefan Fraenkel, CEO, Inceptua Group

We are happy to assume the work of providing this important treatment option to patients and physicians. This global license agreement for JETREA® is an important building block for Inceptua. As both a pharmaceutical company and a service partner, we are committed to bringing treatments to patients in need through a business model spanning throughout the product lifecycle and building on our combined expertise in both commercialization of specialty and rare disease products, clinical trial comparator sourcing, packaging, labelling, and distribution solutions, as well as access programs for pre-approval and un-licensed medicines,” says Stefan Fraenkel, CEO, Inceptua Group, and continues:

“Having been established for more than 20 years, we have a solid infrastructure with industry-leading capabilities and operations across North America, Europe, and Asia.

JETREA® was launched in early 2013, and over 35,000 patients have been treated with the product to-date with real world clinical data confirming that the drug is a safe and effective early treatment for a well identified group of patients suffering from symptomatic vitreomacular adhesion or vitreomacular traction.

The EU Marketing Authorization and global distribution rights will be transferred to the Inceptua Group during 2020, and will vary by region. In Europe, the Marketing Authorization transfer is expected to be completed by Summer 2020.

 

About Inceptua

Inceptua is a pharmaceutical company and service partner spanning throughout the product lifecycle – from clinical trial comparator sourcing, packaging, labelling, and distribution solutions, through early access and unlicensed medicines programs to licensing and commercialization of products.

Inceptua partners with life science companies of all sizes, drawing on over 20 years of industry experience:

  • Inceptua Pharma commercializes and market orphan and specialty care products and have the expertise and capabilities to supply unlicensed medicines globally
  • Inceptua Services supports pharma and biotech companies with global clinical trial comparator sourcing, packaging and labelling solutions, pre-approval and medicines access programs and consulting

Inceptua has global operations with local offices across Europe, USA, and Asia.

www.inceptua.com

 

For further information, please contact:

Jeremy Broadis

Head of Corporate Development

jeremy.broadis@inceptua.com

Direct: +44 20 39107 617

 

Morten Grøn

Communications

morten.gron@inceptua.com

Mobile: +45 2556 4781